Healthcare Equipment and Supplies
Company Overview of VertiFlex Inc.
VertiFlex Inc., a medical device company, develops minimally invasive solutions for the treatment of lumbar spinal stenosis (LSS). It offers Superion Interspinous Spacer, a motion-preserving, indirect decompression spinal implant system for the treatment of moderate lumbar spinal stenosis. The company also provides Totalis Direct Decompression System specialized instruments to safely perform minimally invasive direct decompressions of the lumbar spine. VertiFlex Inc. was formerly known as DK Spine Technology Inc. The company was incorporated in 2004 and is based in San Clemente, California.
1351 Calle Avanzado
San Clemente, CA 92673
Founded in 2004
Key Executives for VertiFlex Inc.
Chief Executive Officer, President and Director
Chief Financial Officer and Vice President
Vice President of Operations
Vice President of Clinical & Regulatory Affairs
Vice President of US Sales
Compensation as of Fiscal Year 2014.
VertiFlex Inc. Key Developments
VertiFlex Announces FDA Advisory Panel Support for the Superion® Interspinous Spacer
Feb 23 15
VertiFlex Inc. announced that the U.S. Food and Drug Administration’s (FDA) Orthopedic and Rehabilitation Devices Advisory Panel has voted strongly in support of the PreMarket Approval application for the company’s Superion® Interspinous Spacer System. The Panel voted that Superion demonstrated safety, effectiveness, and a favorable risk benefit profile based on the results from a 470 patient, multi-center, prospective and randomized controlled IDE trial.
VertiFlex Inc. Presents at 12th Annual 2014 Musculoskeletal New Ventures Conference, Oct-28-2014 11:00 AM
Oct 21 14
VertiFlex Inc. Presents at 12th Annual 2014 Musculoskeletal New Ventures Conference, Oct-28-2014 11:00 AM. Venue: FedEx Institute of Technology, University of Memphis, Memphis, Tennessee, United States.
VertiFlex Inc. Announces Publication of Superion(R) IDE Trial Results
Jul 16 14
VertiFlex Inc. announced publication of two-year clinical results of the Superion(R) Indirect Decompression System. Dr. Vikas Patel, from the University of Colorado, and colleagues, reported outcomes from the first 250 patients enrolled in a prospective, multi-center, randomized FDA IDE trial comparing results of the minimally invasive Superion Indirect Decompression System to an alternative surgical control device. The Superion IDE trial involved enrollment of 470 patients at 31 centers across the United States. Patients were randomized 1:1 to either the Superion System or the commercially available X-STOP IPD. Superion is designed to achieve indirect spinal decompression for patients suffering from Neurogenic Intermittent Claudication due to moderate lumbar spinal stenosis. Superion is implanted minimally invasively through a cannula about the size of a dime and typically performed under local anesthesia.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 22, 2014
Most Searched Private Companies
Sponsored Financial Commentaries